Meeting
2022 ASCO Annual Meeting
A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.
Authors
Stephanie Lheureux
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Stephanie Lheureux , Husam Alqaisi , David E. Cohn , Jing-Yi Chern , Linda R. Duska , Andrea Jewell , Bradley Corr , Ira Seth Winer , Eugenia Girda , Marta A. Crispens , Neesha C. Dhani , Robert C. Grant , Saranya Uthayakumaran , Crystal Lee , Valerie Bowering , Horace Wong , Lisa Wang , Philippe L. Bedard , Jeffrey Moscow , Amit M. Oza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03587311
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5514)
DOI
10.1200/JCO.2022.40.16_suppl.5514
Abstract #
5514
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
First Author: Stephanie Gaillard
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.
First Author: Nehal J. Lakhani
Poster
2023 ASCO Annual Meeting
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
First Author: Yoo Na Kim
Poster
2022 ASCO Annual Meeting
MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).
First Author: Leslie M. Randall